U.S. market Closed. Opens in 11 hours 49 minutes

HOWL | Werewolf Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue19.94M16.40MN/AN/AN/A
Cost of Revenue1.76M2.51M735.00K777.00K463.00K
Gross Profit18.18M13.89M-735.00K-777.00K-463.00K
Operating Expenses58.68M72.46M50.09M22.40M9.94M
Selling, General & Admin16.91M18.70M14.82M5.76M3.60M
Research & Development41.78M53.76M35.27M16.64M6.34M
Other Operating Expenses-1.14M2.25M104.00K7.26M430.00K
Operating Income-40.50M-56.06M-50.09M-22.40M-9.94M
Other Expenses / Income3.13M2.25M104.00K7.36M-312.00K
Before Tax Income-37.37M-53.81M-49.98M-15.04M-10.25M
Income Tax Expenses1.60M-2.25M-216.00K-101.00K742.00K
Net Income-37.37M-51.56M-49.77M-14.94M-10.99M
Interest Expenses3.14M-1.10MN/AN/A372.00K
Basic Shares Outstanding35.65M28.86M27.31M28.66M28.66M
Diluted Shares Outstanding35.65M28.86M27.31M28.66M28.66M
EBITDA-38.74M-56.06M-50.09M-22.25M-9.54M
EBITDA Margin-194.25%-341.78%0.00%0.00%0.00%
EBIT-32.63M-54.91M-49.98M-15.04M-9.88M
EBIT Margin-163.63%-334.82%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙